Grand Opening of Beijing Honglin Pharmaceutical CBD Office

On March 31st, during the Spring season, Beijing Honglin CBD Office was opened in Beijing downtown.

JUPOPHON^® Ibuprofen Sustained-release Capsules Got the Consistency Evaluation Certified

VIPs of the Huairou District Political Consultative Conference and Huairou District Health Commission Visited Beijing Honglin

On September 9, 2021, VIPs of the Huairou District Political Consultative Conference (HDPCC) and Huairou District Health Commission visited the Beijing Honglin pharmaceutical Co..

RoToFier^® Won the Bid in the 5th National Centralized Procurement of Drugs

On June 23rd, the result of the 5th Round National Governmental Bid for Centralized Procurement of Drugs was released,

Beijing Honglin Amlodipine Besylate Tablet Passed the Consistency Evaluation

Recently, following the JOPOPINE® (Nefedipine Controlled-release Tablets) and RoToFier® (Glipizide Extended Release Tablets).

JUPOPINE^® (Nifedipine Controlled-release Tablets) Passed the Consistency Evaluation

JUPOPINE® (Nifedipine Controlled-release Tablets), in 2010, due to the contemporary rules of naming system,

VIP Guests of China Resources Pharmaceutical Group Limited Visit Beijing Honglin

On March 24th, 2021, Guests of China Resources Pharmaceutical Group Ltd.

RoToFier^® Glipizide Extended Release Tablets Got the Consistency Evaluation Certified

RoToFier^® Glipizide Extended Release Tablets got the Consistency Evaluation Certified